Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. The landscape of the systemic treatment for advanced HCC is changing quickly, and recently, the standard of care became either atezolizumab plus bevacizumab or tremelimumab plus durvalumab in t...

Descripción completa

Detalles Bibliográficos
Autores principales: De Wilde, Nika, Vonghia, Luisa, Francque, Sven, De Somer, Thomas, Bagdadi, Ali, Staub, Eva, Lambrechts, Jasper, Bucalau, Ana-Maria, Verset, Gontran, Van Steenkiste, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453466/
https://www.ncbi.nlm.nih.gov/pubmed/36157862
http://dx.doi.org/10.4254/wjh.v14.i8.1608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453466/
https://www.ncbi.nlm.nih.gov/pubmed/36157862
http://dx.doi.org/10.4254/wjh.v14.i8.1608

Ejemplares similares